Research Finds 12-Week GH Pretreatment Boosts Embryo Quality in Women with Past IVF Failures

Could a simple change in pretreatment duration make all the difference for women struggling with poor embryo quality during IVF? For clinicians, addressing persistently low-quality embryos in IVF can feel like solving a puzzle with missing pieces. New research published in BMC Pregnancy and Childbirth explores whether extending growth hormone (GH) pretreatment can help unlock better outcomes for this challenging population.

Study Overview: Real-World Evidence from a Chinese IVF Center

This retrospective cohort study analyzed 192 women under 38 years old who had a history of poor-quality embryos in prior IVF cycles. Patients were divided into three groups:

No GH pretreatment

GH pretreatment for 2–4 weeks

GH pretreatment for 12 weeks

The main focus was on embryo quality at day 3 (D3), blastocyst formation rates, and live birth outcomes.

Prolonged GH: A Game-Changer for Embryo Quality

Findings showed that women who received 12 weeks of GH pretreatment had a significantly higher rate of good-quality D3 embryos (46%) compared to those with no GH (26%) or short-term GH (31%). The benefit was consistent even after adjusting for ovarian stimulation protocols and other baseline factors.

Mechanisms: Why Might Longer GH Pretreatment Help?

Growth hormone is thought to act through the GH/IGF-1 axis, supporting follicular development, oocyte maturation, and reducing oxidative stress. Notably, the time required for a follicle to mature from its earliest stage is around 85 days—suggesting that a longer GH exposure period could more fully support these key processes.

Clinical Outcomes: Live Birth Rates and Limitations

The study also found that fresh embryo transfer live birth rates were higher in the prolonged GH group (57%) versus those with no GH (26%). However, cumulative live birth rates (including both fresh and frozen transfers) did not differ significantly across groups. The authors note that selection criteria, small sample sizes, and the retrospective design may limit how broadly these findings can be applied.

What This Means for Practice

For reproductive specialists, prolonged GH pretreatment may be a valuable tool for patients with a history of poor embryo quality despite adequate ovarian reserve. These results highlight the importance of considering follicular biology—and not just cycle protocols—when tailoring IVF strategies.

Conclusion

For women facing repeated IVF failures due to poor embryo quality, 12 weeks of growth hormone pretreatment may offer real improvements in embryo development. While more research is needed, this study provides actionable insights for clinicians aiming to optimize outcomes for this difficult-to-treat group.

Key Points

Prolonged (12-week) GH pretreatment improved D3 embryo quality for women with previously poor IVF outcomes.

Shorter GH protocols (2–4 weeks) showed only modest benefit compared to no GH.

Live birth rates after fresh transfer were higher with prolonged GH, but cumulative live birth rates were similar.

The biological rationale supports longer GH exposure aligning with the natural timeline of folliculogenesis.

Careful patient selection and further prospective research are needed before routine adoption.

Citation: Liu C, Wang P, Pan P, Yang H, Huang X. Prolonged growth hormone pretreatment is associated with improved embryo quality in women with poor quality embryos in previous IVF cycles. BMC Pregnancy and Childbirth. 2026; [in press]. https://doi.org/10.1186/s12884-026-09825-4